CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Kiora Pharmaceuticals Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Kiora Pharmaceuticals Inc
332 ENCINITAS BOULEVARD, SUITE 102
Phone: (781) 788-8869p:781 788-8869 ENCINITAS, CA  92024  United States Ticker: KPRXKPRX
Business Summary
Kiora Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing and commercializing therapies for the treatment of orphan retinal diseases. Its pipeline consists of three product candidates, including KIO-301, KIO-104, KIO-101 and KIO-201. Its lead product, KIO-301, is a vision-restoring small molecule that is designed to restore vision in patients with inherited and age-related degenerative retinal diseases, including retinitis pigmentosa (RP). KIO-104 is a next generation, non-steroidal, immuno-modulatory, small-molecule inhibitor of Dihydroorotate Dehydrogenase (DHODH), which is being develop for the treatment of Posterior Non-Infectious Uveitis, a rare T cell-mediated, intraocular inflammatory disease. KIO-101 focuses on treating the ocular manifestation of patients with autoimmune diseases, including rheumatoid arthritis, and as such is termed the Ocular Presentation of Rheumatoid Arthritis and Other Autoimmune Diseases (OPRA+).

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board PraveenTyle 64 9/20/2023 6/1/2008
President, Chief Executive Officer, Director Brian M.Strem 44 12/1/2022 7/23/2021
Chief Financial Officer MelissaTosca 44 7/1/2024 9/13/2022
5 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Panoptes Pharma GES. M.B.H Reisnerstrasse 34/1 Wien Austria

Business Names
Business Name
Bayon Therapeutics, Inc.
EYEG
Jade Therapeutics, Inc.
4 additional Business Names available in full report.

General Information
Number of Employees: 12 (As of 12/31/2023)
Outstanding Shares: 3,000,788 (As of 11/6/2024)
Shareholders: 59
Stock Exchange: NASD
Federal Tax Id: 980443284
Fax Number: (302) 636-5454
Email Address: contact@eyegatepharma.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, December 3, 2024